Hypertension treatment in the Asia-Pacific: the role of and treatment strategies with nebivolol

Kim, Cheol Ho; Abelardo, Nelson S.; Buranakitjaroen, Peera; Krittayaphong, Rungroj; Lim, Chin Hock; Park, Sungha; Pham, Nguyen Vinh; Rogelio, Gregorio; Wong, Bernard; Low, Lip Ping

doi:10.1136/heartasia-2015-010656

Cited by 6 publications

(4 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…are dose‐dependent, cardio‐selective (relatively β 1 ‐selective) drugs, which thereby offer a more favourable side effect profile . Third‐generation drugs (nebivolol, carvedilol, labetalol) show additionally vasodilatory properties beyond the β‐blockade, and allegedly offer a better haemodynamic profile along with fewer unfavourable metabolic side effects . The common drugs vary in several other parameters regarding pharmacokinetics, intrinsic sympathetic activity (ISA) and in anti‐arrhythmic effects (often referred as "membrane stabilizing activity" (MSA)), that can be explained by additional targeting of cardiac and/or neuronal voltage‐gated sodium channels .…”

Section: Methodsmentioning

confidence: 99%

“…12 Third-generation drugs (nebivolol, carvedilol, labetalol) show additionally vasodilatory properties beyond the β-blockade, and allegedly offer a better haemodynamic profile along with fewer unfavourable metabolic side effects. [13][14][15][16][17][18][19] The common drugs vary in several other parameters regarding pharmacokinetics, intrinsic sympathetic activity (ISA) and in anti-arrhythmic effects (often referred as "membrane stabilizing activity" (MSA)), that can be explained by additional targeting of cardiac and/or neuronal voltage-gated sodium channels. 20 This effect is similar to the MSA of Na + -channels blockers that represent class I anti-arrhythmic drugs.…”

Section: Nebivolol and Metabolic Properties 24mentioning

confidence: 99%

See 1 more Smart Citation

Nebivolol in the treatment of arterial hypertension

Olawi

Krüger

Grimm

et al. 2019

Basic Clin Pharma Tox

View full text Add to dashboard Cite

This MiniReview reports the current knowledge about the treatment of arterial hypertension with the third‐generation beta‐adrenoceptor antagonist (BAA) nebivolol. Furthermore, it reviews the advantages of nebivolol compared to the earlier generation of BAAs with respect to their different pharmacological properties. Beta‐adrenoceptor antagonists are a class of drugs applied for several different conditions, including hypertension and heart failure. They differ significantly in their pharmacological properties, including varying β1/β2‐selectivity and/or exertion of additive effects on the heart and circulation. Although these drugs have been a part of hypertensive therapy for about 40 years, the outcome of large clinical trials has put the role of BAAs into question. However, most of these results were based on first‐ and second‐generation BAAs and cannot be translated directly into third‐generation drugs. The third‐generation BAA nebivolol has the highest β1‐selectivity seen so far, together with additional vasodilating and anti‐oxidative properties. It is currently applied in the treatment of hypertension and congestive heart failure. Nebivolol has a unique pharmacological profile, despite showing similar blood pressure‐lowering effects, and has certain advantages in the treatment of hypertension compared to the previous generations of BAAs. This includes significant improvements in endothelial dysfunction, central haemodynamics and the degree of erectile dysfunction in men, a neutral/beneficial metabolic profile and lastly a more favourable side effect profile. It is widely beneficial for, for example, sexually active men and patients with comorbidities such as type II diabetes mellitus, metabolic syndrome and chronic obstructive lung disorders. Whether the advantages translate to an improved long‐term clinical outcome remains to be clarified, and ongoing prospective studies will show this in the future.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Nebivolol and Metabolic Properties 24mentioning

confidence: 99%

Nebivolol in the treatment of arterial hypertension

Olawi

Krüger

Grimm

et al. 2019

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…On the contrary, not all β-blockers show such adverse effects on glucose homeostasis. Carvedilol, nebivolol, labetalol and third-generation β-blockers not only block β-adrenoreceptors, but also show additional properties promoting vasodilatation and resulting in less adverse effects on metabolism [ 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 ]. The Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial involved patients with T2D and hypertension.…”

Section: Standard Antihypertensive Drugs In the Therapy Of Patients W...mentioning

confidence: 99%

Hypertension and Type 2 Diabetes—The Novel Treatment Possibilities

Przezak

Bielka

Pawlik

2022

IJMS

View full text Add to dashboard Cite

Elevated blood pressure and hyperglycaemia frequently coexist and are both components of metabolic syndrome. Enhanced cardiovascular risk is strongly associated with diabetes and the occurrence of hypertension. Both hypertension and type 2 diabetes, if treated inappropriately, lead to serious complications, increasing the mortality of patients and generating much higher costs of health systems. This is why it is of great importance to find the missing link between hypertension and diabetes development and to simultaneously search for drugs influencing these two disorders or even drugs aimed at their pathological bases. Standard antihypertensive therapy mainly focuses on blood pressure reduction, while novel drugs also possess a wide range of pleiotropic modes of actions, such as cardio- and nephroprotective properties or body weight reduction. These properties are especially desirable in a situation when type 2 diabetes coexists with hypertension. This review describes the connections between diabetes and hypertension development and briefly summarises the current knowledge regarding attempts to define targets for the treatment of high blood pressure in diabetic patients. It also describes the standard hypotensive drugs preferred in patients with type 2 diabetes, as well as novel drugs, such as finerenone, esaxerenone, sodium–glucose co-transporter-2 inhibitors, glucagon-like peptide-1 analogues and sacubitril/valsartan.

show abstract

“…Additionally, newer BBs such as nebivolol have direct peripheral vasodilatory activity and other properties which distinguish them from first-generation and second-generation agents (table 1). In this issue of Heart Asia , Kim et al 2 commend the use of BBs, and specifically nebivolol, as a first-line agent for HBP.…”

mentioning

confidence: 99%

Nebivolol as a first-line antihypertensive: a justifiable proposal?: Table 1

Ling

2016

Heart Asia

View full text Add to dashboard Cite

Hypertension treatment in the Asia-Pacific: the role of and treatment strategies with nebivolol

Cited by 6 publications

References 62 publications

Nebivolol in the treatment of arterial hypertension

Nebivolol in the treatment of arterial hypertension

Hypertension and Type 2 Diabetes—The Novel Treatment Possibilities

Nebivolol as a first-line antihypertensive: a justifiable proposal?: Table 1

Contact Info

Product

Resources

About